Epstein-Barr virus (EBV) reactivation and therapeutic inhibitors.
Kerr JR.
J Clin Pathol. 2019 Oct;72(10):651-658. doi: 10.1136/jclinpath-2019-205822. Epub 2019 Jul 17.
Infectious Mononucleosis.
Dunmire SK, Hogquist KA, Balfour HH.
Curr Top Microbiol Immunol. 2015;390(Pt 1):211-40. doi: 10.1007/978-3-319-22822-8_9.
Epstein-Barr Virus and Systemic Autoimmune Diseases.
Houen G, Trier NH.
Front Immunol. 2021 Jan 7;11:587380. doi: 10.3389/fimmu.2020.587380. eCollection 2020.
Virological Markers in Epstein-Barr Virus-Associated Diseases.
Lupo J, Truffot A, Andreani J, Habib M, Epaulard O, Morand P, Germi R.
Viruses. 2023 Feb 28;15(3):656. doi: 10.3390/v15030656.
Progress and problems in understanding and managing primary Epstein-Barr virus infections.
Odumade OA, Hogquist KA, Balfour HH Jr.
Clin Microbiol Rev. 2011 Jan;24(1):193-209. doi: 10.1128/CMR.00044-10.
Treatment of Epstein-Barr Virus infection in immunocompromised patients.
Pociupany M, Snoeck R, Dierickx D, Andrei G.
Biochem Pharmacol. 2024 Jul;225:116270. doi: 10.1016/j.bcp.2024.116270. Epub 2024 May 10.
The EB virus.
Epstein MA, Achong BG.
Annu Rev Microbiol. 1973;27:413-36. doi: 10.1146/annurev.mi.27.100173.002213.
Asymptomatic infection with EB virus.
Sutton RN, Marston SD, Almond EJ, Reynolds K, Pounds FJ.
J Clin Pathol. 1974 Feb;27(2):97-100. doi: 10.1136/jcp.27.2.97.
[EB virus infection].
Kawa K.
Nihon Rinsho Meneki Gakkai Kaishi. 1996 Dec;19(6):583-7.
Vaccination against EB virus.
[No authors listed]
Br Med J. 1976 Dec 18;2(6050):1467-8.
